Tumor vaccines.
Melanoma vaccines are an exciting and increasingly attractive immunotherapeutic approach for malignant melanoma. Vaccines can be used for patients with high risk primary melanoma and regional disease, stages in the progression of melanoma for which there is presently no treatment. They are unique in their potential to prevent cancer in high risk individuals. Multiple approaches are being followed to develop effective vaccines. It is too early to judge whether any of them effectively slow the progression of melanoma. However, it is clear that vaccines are safe to use, and that they can stimulate immune responses to melanoma in some patients. The specificity of these responses needs to be clarified, and multiple challenges remain to be overcome before effective vaccines to melanoma become available. We must first identify the antigens on melanoma that stimulate immune responses, define the immune effector mechanisms that are stimulated by vaccine immunization and identify those responsible for increasing resistance to tumor growth, devise appropriate ways of constructing vaccines that will induce such responses, and find adjuvants and/or immunodulators that will potentiate desirable immune responses.
Melanoma Program, Kaplan Cancer Center, New York University School of Medicine, NY 10016.
J C
JC
Bystryn
D000818:Animals; D006801:Humans; D007167:Immunotherapy; D008545:Melanoma / Q000517:prevention & control / Q000628:therapy; D009369:Neoplasms / Q000276:immunology / Q000517:prevention & control / Q000628:therapy*; D014612:Vaccines
D014612:Vaccines